CN101180261A - 用于制备盐酸西那卡塞晶型ⅰ的方法 - Google Patents

用于制备盐酸西那卡塞晶型ⅰ的方法 Download PDF

Info

Publication number
CN101180261A
CN101180261A CNA2006800179392A CN200680017939A CN101180261A CN 101180261 A CN101180261 A CN 101180261A CN A2006800179392 A CNA2006800179392 A CN A2006800179392A CN 200680017939 A CN200680017939 A CN 200680017939A CN 101180261 A CN101180261 A CN 101180261A
Authority
CN
China
Prior art keywords
cinacalcet hydrochloride
cinacalcet
solvent
hours
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800179392A
Other languages
English (en)
Chinese (zh)
Inventor
R·利夫什茨-利伦
S·阿夫哈-麦丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN101180261A publication Critical patent/CN101180261A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82Purification; Separation; Stabilisation; Use of additives
    • C07C209/84Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82Purification; Separation; Stabilisation; Use of additives
    • C07C209/90Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)
CNA2006800179392A 2005-05-23 2006-05-23 用于制备盐酸西那卡塞晶型ⅰ的方法 Pending CN101180261A (zh)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US68415205P 2005-05-23 2005-05-23
US60/684,152 2005-05-23
US69698105P 2005-07-05 2005-07-05
US60,696,981 2005-07-05
US69711105P 2005-07-06 2005-07-06
US60/697,111 2005-07-06
US69861305P 2005-07-11 2005-07-11
US60/698,613 2005-07-11
US70123205P 2005-07-20 2005-07-20
US60/701,232 2005-07-20
US70291805P 2005-07-26 2005-07-26
US60/702,918 2005-07-26
US70691005P 2005-08-09 2005-08-09
US60/706,910 2005-08-09
US73005005P 2005-10-24 2005-10-24
US60/730,050 2005-10-24
US73208305P 2005-10-31 2005-10-31
US60/732,083 2005-10-31
US73300805P 2005-11-02 2005-11-02
US60/733,008 2005-11-02
US73466905P 2005-11-07 2005-11-07
US60/734,669 2005-11-07
US73512605P 2005-11-08 2005-11-08
US60/735,126 2005-11-08
US73882705P 2005-11-21 2005-11-21
US60/738,827 2005-11-21
US74178705P 2005-12-01 2005-12-01
US60/741,787 2005-12-01
US75091005P 2005-12-15 2005-12-15
US60/750,910 2005-12-15
US79480406P 2006-04-24 2006-04-24
US60/794,804 2006-04-24
PCT/US2006/020304 WO2006127933A1 (en) 2005-05-23 2006-05-23 Processes for preparing cinacalcet hydrochloride crystal form i

Publications (1)

Publication Number Publication Date
CN101180261A true CN101180261A (zh) 2008-05-14

Family

ID=37101358

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800179392A Pending CN101180261A (zh) 2005-05-23 2006-05-23 用于制备盐酸西那卡塞晶型ⅰ的方法

Country Status (12)

Country Link
US (2) US7294735B2 (enExample)
EP (3) EP1883618B1 (enExample)
JP (3) JP4638491B2 (enExample)
KR (2) KR20070088485A (enExample)
CN (1) CN101180261A (enExample)
AT (1) ATE445587T1 (enExample)
CA (2) CA2605736A1 (enExample)
ES (1) ES2334260T3 (enExample)
IL (2) IL185108A0 (enExample)
MX (1) MX2007000983A (enExample)
TW (1) TW200716512A (enExample)
WO (2) WO2006127932A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739500A (zh) * 2012-12-27 2014-04-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
CN104892428A (zh) * 2015-06-05 2015-09-09 南京辰逸生物科技有限公司 一种盐酸西那卡塞的制备方法
CN105439818A (zh) * 2015-12-31 2016-03-30 苏州汇和药业有限公司 一种西那卡塞中间体3-(3-三氟甲基苯基)丙醇的合成方法
CN107879939A (zh) * 2016-09-30 2018-04-06 上海天慈生物谷生物工程有限公司 一种制备 n‑((1r)‑1‑(1‑萘基)乙基)‑3‑(3‑(三氟甲基)苯基)丙‑1‑胺盐酸盐的方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645494C (en) * 2006-03-23 2016-01-12 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
EP1913941A1 (en) * 2006-10-19 2008-04-23 Sandoz AG Polymorphic forms and solvates of Cinacalcet hydrochloride
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
WO2008000423A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Crystalline form of cinacalcet
US20080181959A1 (en) * 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
WO2008058236A2 (en) * 2006-11-08 2008-05-15 Dr. Reddy's Labortories, Ltd. Methods for preparing cinacalcet hydrochloride
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
ITMI20071261A1 (it) 2007-06-22 2008-12-23 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2009039241A2 (en) * 2007-09-18 2009-03-26 Medichem, S.A. Improved process for preparing cinacalcet hydrochloride
US7696372B2 (en) * 2007-10-01 2010-04-13 Ascenta Therapeutics, Inc. Process for preparing R-gossypol L-phenylalaninol dienamine
US20110189241A1 (en) * 2008-05-05 2011-08-04 Medichem, S.A. Process For Controlling The Particle Size of A [3-(Trifluoromethyl)Phenyl]-1-Aminopropane Derivative
EP2321256B1 (en) * 2008-06-18 2014-11-12 ERREGIERRE S.p.A. Process for the synthesis of cinacalcet hydrochloride
EP2328860A2 (en) * 2008-08-06 2011-06-08 Actavis Group PTC EHF Unsaturated cinacalcet salts and processes for preparing cinacalcet hydrochloride
US20110318417A1 (en) * 2008-12-08 2011-12-29 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
EP2398763A2 (en) 2009-02-19 2011-12-28 ZaCh System S.p.A. Process for preparing cinacalcet hydrochloride
US8575393B2 (en) 2009-03-05 2013-11-05 Cipla Limited Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process
WO2010128388A2 (en) 2009-05-08 2010-11-11 Aurobindo Pharma Limited An improved process for the preparation of intermediate compounds useful for the preparation of cinacalcet
CN102548955B (zh) 2009-09-10 2014-06-04 Zach系统股份公司 用于制备西那卡塞特的方法
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
IT1396623B1 (it) 2009-11-26 2012-12-14 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet e suoi intermedi
CZ2011770A3 (cs) * 2011-11-25 2013-01-16 Zentiva, K.S. Zpusob výroby Cinacalcetu
CN103450027B (zh) 2012-05-29 2015-07-29 上海京新生物医药有限公司 盐酸西那卡塞的制备方法
FR2995307A1 (fr) 2012-09-07 2014-03-14 Prod Chim Auxiliaires Et De Synthese Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables
CN103193655B (zh) * 2013-04-15 2015-06-24 山东新华制药股份有限公司 盐酸西那卡塞晶型ⅰ的制备方法
CN104512864B (zh) * 2013-09-30 2017-08-22 中国石油化工股份有限公司 一种低温脱除微量碳氧化物的方法
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
BR102015025502B1 (pt) * 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
CN106610404B (zh) * 2015-10-21 2019-01-15 华仁药业股份有限公司 采用hplc法检测盐酸西那卡塞同分异构体的方法
KR20200022712A (ko) 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
CN109096119B (zh) * 2018-10-29 2019-10-25 江苏永安制药有限公司 一种制备盐酸西那卡塞的方法
CN110041206B (zh) * 2019-04-29 2021-10-19 梯尔希(南京)药物研发有限公司 一种西那卡塞杂质的制备方法
CN111153832B (zh) * 2020-01-20 2022-02-25 广州九植医药科技有限公司 一种西那卡塞杂质的制备方法
KR20250003360A (ko) * 2023-06-30 2025-01-07 주식회사 종근당 화합물의 신규한 제조방법 및 신규한 결정형

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966988A (en) * 1989-02-17 1990-10-30 Chevron Research Company Process for preparing acetonitrile 3-trifluoromethyl benzene
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
HU228150B1 (en) * 1994-10-21 2012-12-28 Nps Pharma Inc Calcium receptor-active compounds, medicaments comprising them, and the use of said medicaments
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
EP0907631B1 (en) * 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
US7829595B2 (en) * 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739500A (zh) * 2012-12-27 2014-04-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
CN103739500B (zh) * 2012-12-27 2016-03-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
CN104892428A (zh) * 2015-06-05 2015-09-09 南京辰逸生物科技有限公司 一种盐酸西那卡塞的制备方法
CN105439818A (zh) * 2015-12-31 2016-03-30 苏州汇和药业有限公司 一种西那卡塞中间体3-(3-三氟甲基苯基)丙醇的合成方法
CN107879939A (zh) * 2016-09-30 2018-04-06 上海天慈生物谷生物工程有限公司 一种制备 n‑((1r)‑1‑(1‑萘基)乙基)‑3‑(3‑(三氟甲基)苯基)丙‑1‑胺盐酸盐的方法

Also Published As

Publication number Publication date
JP2008507566A (ja) 2008-03-13
EP1805135A2 (en) 2007-07-11
US7294735B2 (en) 2007-11-13
ES2334260T3 (es) 2010-03-08
WO2006127933A1 (en) 2006-11-30
EP1883618B1 (en) 2009-10-14
US20070060645A1 (en) 2007-03-15
JP2010280715A (ja) 2010-12-16
KR20070088485A (ko) 2007-08-29
IL185108A0 (en) 2007-12-03
MX2007000983A (es) 2007-04-16
ATE445587T1 (de) 2009-10-15
IL185494A0 (en) 2008-01-06
JP4638491B2 (ja) 2011-02-23
US20070099998A1 (en) 2007-05-03
US7247751B2 (en) 2007-07-24
CA2606099A1 (en) 2006-11-30
WO2006127932A2 (en) 2006-11-30
WO2006127932A3 (en) 2007-02-01
EP1975150A1 (en) 2008-10-01
JP2008507565A (ja) 2008-03-13
KR20070083471A (ko) 2007-08-24
CA2605736A1 (en) 2006-11-30
EP1883618A1 (en) 2008-02-06
WO2006127933A8 (en) 2007-08-30
TW200716512A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
CN101180261A (zh) 用于制备盐酸西那卡塞晶型ⅰ的方法
JP2008507566A6 (ja) シナカルセト塩酸塩結晶フォームiの調製方法
CN102093360B (zh) 二氢蝶啶酮衍生物的制备方法
CN104610250A (zh) 含三个氮杂环的1,2,3-噻二唑-5-甲脒类化合物及合成
EP2480534A1 (en) Process for the preparation of sorafenib tosylate
CN114249694A (zh) 一种特格拉赞中间体的制备方法
CN106083826A (zh) 一种厄贝沙坦异构体及其中间体的制备方法
CN101014584A (zh) 结晶霉酚酸钠的制备方法
CN103880829B (zh) 一种阿齐沙坦晶体及其制备方法和用途
CN116874392B (zh) 一种非甾体选择性盐皮质激素受体拮抗剂中间体4-醛基-3-甲氧基苯腈的制备方法
KR101501253B1 (ko) 결정성 페북소스타트 피돌레이트 염 및 이의 제조 방법
CN108707137B (zh) 一种吡蚜酮的制备方法
CN103467445A (zh) 苯甲酸阿格列汀的制备方法
WO2021179540A1 (zh) 一种伐度司他及其中间体的制备方法
CN111116476A (zh) 制备抗肿瘤药物多拉米胺的方法
CN105753735B (zh) 一种高效低毒加压素拮抗药物的制备方法
CN102675294A (zh) 一种合成氯沙坦及其中间体的方法
CN103524483B (zh) 一种苯甲酸阿格列汀的制备方法
CN109180511A (zh) 一种盐酸丁卡因的制备方法
US20050209460A1 (en) Process for the preparation of torsemide and related intermediates
CN110606826A (zh) 托拉塞米钠一水合物、其晶型及组合物
JPH05201903A (ja) 2−(2,4−ジヒドロキシフェニル)−2−(4−ヒドロキシフェニル)プロパンの製造方法
CN109354581A (zh) 一种曲昔派特的制备方法
WO2004092107A1 (ja) パラヒドロキシ安息香酸無水和物の結晶およびその製造方法
CN120398868A (zh) 一种抗疱疹病毒药物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080514